From the 42nd Annual Renaissance Ball in Philadelphia benefiting the Crohn's & Colitis Foundation, host Lu Ann Cahn talks with Dr. David Piccoli, Chief of the Division of Gastroenterology, Hepatology and Nutrition, Director of the Biesecker PediatricLiver Center, and a board-certified pediatric gastroenterologist at Children's Hospital of Philadelphia. Dr. Piccoli discusses the RISK study, supported by the Crohn’s & Colitis Foundation, and the challenges patients face with response to treatment. This pediatric study enrolled 1,800 patients at the time of their diagnosis and collected clinical, genetic, treatment and microbiome information to help to determine how the immune system works over time.
RISK Cohort Study in Crohn's Disease
Lu Ann Cahn talks w/ Dr. Piccoli about the RISK study that enrolled 1,800 patients & collected a variety of info to learn more about the immune system
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
In Collaboration with
Overview
Publish Date
Release Date: 12/15/2017
Recommended
Details
In Collaboration with
Overview
From the 42nd Annual Renaissance Ball in Philadelphia benefiting the Crohn's & Colitis Foundation, host Lu Ann Cahn talks with Dr. David Piccoli, Chief of the Division of Gastroenterology, Hepatology and Nutrition, Director of the Biesecker PediatricLiver Center, and a board-certified pediatric gastroenterologist at Children's Hospital of Philadelphia. Dr. Piccoli discusses the RISK study, supported by the Crohn’s & Colitis Foundation, and the challenges patients face with response to treatment. This pediatric study enrolled 1,800 patients at the time of their diagnosis and collected clinical, genetic, treatment and microbiome information to help to determine how the immune system works over time.
Publish Date
Release Date: 12/15/2017
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE Broadcast Replay
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
1.00 credits
<p>Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease</p>
CME/CE Broadcast Replay
Love Story: Lipid Education for Women’s Heart Health
0.50 credits
<p>Love Story: Lipid Education for Women’s Heart Health</p>
MinuteCE®
Clinical Conundrums in ARIA: 1. Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
1.25 credits
<p>Clinical Conundrums in ARIA: Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies</p>
MinuteCE®
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
1.25 credits
<p>Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy</p>
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credits
<p>Personalizing Care Within the RCC Treatment Paradigm</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?